Funding for this research was provided by:
Advanced Accelerator Applications (N/A)
Received: 19 January 2020
Accepted: 3 December 2020
First Online: 5 January 2021
Ethics approval and consent to participate
: Not applicable. No new patient data were generated as part of this analysis.
: Not applicable.
: OL and JV are current employees of AAA, which manufactures Lutathera. JSP is a current employee of Ossian Health Economics and Communications, which has received consulting fees from AAA. NR has received honoraria/consulting fees from Novartis/AAA, which manufactures Lutathera as well as Roche, Esai and Ipsen.